Boraks P, Seale J, Price J, Bass G, Ethell M, Keeling D, Mahendra P, Baglin T, Marcus R
BMT Unit, Addenbrooke's NHS Trust, Cambridge.
Br J Haematol. 1998 Jun;101(3):483-6. doi: 10.1046/j.1365-2141.1998.00732.x.
Thrombosis is a well-recognized complication following insertion of central venous catheters and is associated with significant morbidity. In an attempt to reduce line-associated thrombosis, 108 consecutive patients with haematological malignancies were commenced on prophylactic 'minidose' warfarin, 1 mg/d, at the time of line insertion. This group of patients were compared with a historic group of 115 consecutive patients who had not received warfarin. Clinically-suspected venous thrombosis was confirmed by Doppler ultrasound or venography. Patients taking prophylactic warfarin had their prothrombin time measured three times per week with the aim of maintaining an INR <1.6. Five (5%) of the 108 patients who received minidose warfarin developed a thrombosis, at a median of 72 d (range 5-166) from the time of catheter insertion. In the 115 patients who were not anticoagulated 15 (13%) developed a catheter-associated thrombosis at a median of 16 d (range 1-35). There was a significant reduction in line-associated thrombosis in patients receiving warfarin (P=0.03). These data suggest that minidose warfarin reduces the incidence of central venous catheter related thrombosis in patients with haematological malignancies.
血栓形成是中心静脉导管插入术后一种公认的并发症,且与显著的发病率相关。为了降低与导管相关的血栓形成风险,108例血液系统恶性肿瘤患者在导管插入时开始接受预防性“小剂量”华法林治疗,剂量为1毫克/天。将这组患者与115例未接受华法林治疗的连续患者的历史队列进行比较。临床怀疑的静脉血栓形成通过多普勒超声或静脉造影确诊。接受预防性华法林治疗的患者每周测量三次凝血酶原时间,目标是维持国际标准化比值(INR)<1.6。108例接受小剂量华法林治疗的患者中有5例(5%)发生了血栓形成,从导管插入时起的中位时间为72天(范围5 - 166天)。在115例未接受抗凝治疗的患者中,有15例(13%)发生了与导管相关的血栓形成,中位时间为16天(范围1 - 35天)。接受华法林治疗的患者中与导管相关的血栓形成显著减少(P = 0.03)。这些数据表明,小剂量华法林可降低血液系统恶性肿瘤患者中心静脉导管相关血栓形成的发生率。